What the AbbVie and Express Script Deal Means for Gilead
AbbVie and Express Scripts have entered into an exclusive agreement under which Express Scripts will distribute AbbVie's hepatitis treatment.
AbbVie and Express Scripts have entered into an exclusive agreement under which Express Scripts will distribute AbbVie's hepatitis treatment.
The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Tuesday's top analyst upgrades and downgrades from 24/7 Wall St. include Cisco Systems, Dreamworks Animation, Lululemon Athletica, Schlumberger and Verizon Communications.
ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or…
24/7 Wall St. has identified five of the lowest performing health care stocks over the past month which need to catch up to peers.
With the markets at or near record highs, the volume of insider selling has reached some of the highest levels this year.
A new research report from the analysts at UBS focuses on four companies that stand to benefit from rising demand for the drugs they produce that treat hepatitis C.
A Gilead Sciences bond offering and a key insider stock sale netting over $14 million should be considered by investors.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.
A new research note from Cowen focuses on health care companies that have released earnings and offer investors reasons to own the stocks.
Gilead Sciences reported disappointing third-quarter results after the market close on Monday.
Gilead Sciences is set to report its third-quarter earnings after the U.S. markets close on Tuesday.
Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.
Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech analysts feels could be a very solid third-quarter earnings season.
In a new research report, Deutsche Bank analysts suggest investors focus on sectors like technology, health care, financials and selected industrials.